Reviva Pharmaceuticals Holdings Inc (RVPH)
1.26
-0.02
(-1.95%)
USD |
NASDAQ |
Jun 25, 16:00
1.26
0.00 (0.00%)
After-Hours: 20:00
Reviva Pharmaceuticals Holdings Research and Development Expense (TTM): 31.97M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 31.97M |
| December 31, 2023 | 31.67M |
| September 30, 2023 | 33.41M |
| June 30, 2023 | 27.00M |
| March 31, 2023 | 22.52M |
| December 31, 2022 | 22.87M |
| Date | Value |
|---|---|
| September 30, 2022 | 15.31M |
| June 30, 2022 | 14.43M |
| March 31, 2022 | 10.29M |
| December 31, 2021 | 4.852M |
| September 30, 2021 | 2.189M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
2.189M
Minimum
Sep 2021
33.41M
Maximum
Sep 2023
19.68M
Average
22.52M
Median
Mar 2023
Research and Development Expense (TTM) Benchmarks
| AbbVie Inc | 7.322B |
| ABVC BioPharma Inc | 0.797M |
| Sutro Biopharma Inc | 197.90M |
| Flora Growth Corp | 0.093M |
| Journey Medical Corp | 13.39M |